Horizon Pharma PLC (HZNP) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been given a consensus recommendation of “Buy” by the fifteen brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.64.

Several research firms have weighed in on HZNP. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Sunday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma in a research report on Sunday, October 22nd. ValuEngine upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. Cowen restated a “buy” rating on shares of Horizon Pharma in a research report on Thursday, September 28th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price objective on shares of Horizon Pharma in a research report on Tuesday, September 26th.

Several large investors have recently modified their holdings of the company. California Public Employees Retirement System grew its position in shares of Horizon Pharma by 3.4% during the 3rd quarter. California Public Employees Retirement System now owns 325,085 shares of the biopharmaceutical company’s stock worth $4,122,000 after buying an additional 10,585 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of Horizon Pharma by 878.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 49,493 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 44,433 shares during the period. Cornerstone Capital Management Holdings LLC. grew its position in shares of Horizon Pharma by 160.3% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 176,200 shares of the biopharmaceutical company’s stock worth $2,233,000 after buying an additional 108,500 shares during the period. Segall Bryant & Hamill LLC grew its position in shares of Horizon Pharma by 8.9% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 643,928 shares of the biopharmaceutical company’s stock worth $8,165,000 after buying an additional 52,454 shares during the period. Finally, Advantage Investment Management LLC grew its position in shares of Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares during the period. Institutional investors own 86.58% of the company’s stock.

Horizon Pharma (NASDAQ:HZNP) traded down $0.16 on Monday, reaching $14.90. 900,244 shares of the company’s stock traded hands, compared to its average volume of 3,356,341. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. The firm has a market cap of $2,440.00, a PE ratio of -4.90, a PEG ratio of 1.28 and a beta of 1.31. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $18.31.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million during the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company’s quarterly revenue was up 30.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 EPS. sell-side analysts expect that Horizon Pharma will post 0.72 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.com-unik.info/2017/12/25/horizon-pharma-plc-hznp-given-consensus-recommendation-of-buy-by-brokerages.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit